Overview

A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma

Status:
Unknown status
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The study is designed to define the immunologic and clinical activity of Tremelimumab in patients with advanced mesothelioma.
Phase:
Phase 2
Details
Lead Sponsor:
Azienda Ospedaliera Universitaria Senese
Treatments:
Antibodies, Monoclonal
Tremelimumab